1. Academic Validation
  2. Erythropoietin regulates energy metabolism through EPO-EpoR-RUNX1 axis

Erythropoietin regulates energy metabolism through EPO-EpoR-RUNX1 axis

  • Nat Commun. 2024 Sep 16;15(1):8114. doi: 10.1038/s41467-024-52352-z.
Weiqin Yin 1 Praveen Kumar Rajvanshi 1 Heather M Rogers 1 Teruhiko Yoshida 2 Jeffrey B Kopp 2 Xiuli An 3 Max Gassmann 4 Constance T Noguchi 5
Affiliations

Affiliations

  • 1 Molecular Medicine Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA.
  • 2 Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA.
  • 3 Laboratory of Membrane Biology, New York Blood Center, New York, NY, USA.
  • 4 Institute of Veterinary Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
  • 5 Molecular Medicine Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA. [email protected].
Abstract

Erythropoietin (EPO) plays a key role in energy metabolism, with EPO receptor (EpoR) expression in white adipose tissue (WAT) mediating its metabolic activity. Here, we show that male mice lacking EpoR in adipose tissue exhibit increased fat mass and susceptibility to diet-induced obesity. Our findings indicate that EpoR is present in WAT, brown adipose tissue, and skeletal muscle. Elevated EPO in male mice improves glucose tolerance and Insulin sensitivity while reducing expression of lipogenic-associated genes in WAT, which is linked to an increase in transcription factor RUNX1 that directly inhibits lipogenic genes expression. EPO treatment in wild-type male mice decreases fat mass and lipogenic gene expression and increase in RUNX1 protein in adipose tissue which is not observed in adipose tissue EpoR ablation mice. EPO treatment decreases WAT ubiquitin Ligase FBXW7 expression and increases RUNX1 stability, providing evidence that EPO regulates energy metabolism in male mice through the EPO-EpoR-RUNX1 axis.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-108470
    99.52%, RUNX1-CBFB Inhibitor